Overview

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow. Giving the patient their healthy stem cells will help their bone marrow make new stem cells that become red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well busulfan, melphalan, and thiotepa work in treating patients who are undergoing an autologous stem cell transplant for Hodgkin's or non-Hodgkin's lymphoma.

Phase:

Phase 2

Details

Lead Sponsor:

OHSU Knight Cancer Institute

Collaborator:

National Cancer Institute (NCI)

Treatments:

Busulfan
Lenograstim
Melphalan
Thiotepa